CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision

Shares of Capricor Therapeutics (CAPR) rose about 8% on Monday after the company said that cardiac results from its HOPE-3 late-stage trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding Research Award in Pediatric Cardiology at the American Heart Association Scientific…